title: Cisplatinum and prednimustine, an active regimen for advanced epithelial ovarian cancer.
abstract: 80 patients with advanced epithelial ovarian carcinoma were treated for 6 months with cisplatinum and prednimustine following initial surgery. Response to treatment was assessed by second-look surgery. The objective response rate was 69% with 38% achieving a complete response for up to 55 months. The toxicity of this regimen was acceptable. Statistically, de-bulking or partial de-bulking had a significant beneficial effect on the likelihood of a complete response. The best survival figures were associated with maximum de-bulking. The combination of cisplatinum and prednimustine is a new and active regimen for operable advanced epithelial ovarian carcinoma.
authors.affiliation: University Department of Clinical Oncology, Western General Hospital, Edinburgh, UK.
authors.forename: J F
authors.initials: JF
authors.lastname: Smyth
authors.forename: G J
authors.initials: GJ
authors.lastname: Beattie
authors.forename: M E
authors.initials: ME
authors.lastname: Stewart
authors.forename: V J
authors.initials: VJ
authors.lastname: Cowie
authors.forename: G E
authors.initials: GE
authors.lastname: Smart
authors.forename: J R
authors.initials: JR
authors.lastname: Livingstone
authors.forename: R C
authors.initials: RC
authors.lastname: Leonard
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage; D004341:Drug Evaluation; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D011238:Prednimustine / Q000008:administration & dosage
chemical_list: D011238:Prednimustine; D002945:Cisplatin